Advertise on podcast: The Psychedelic Therapy Podcast

"We can pass 10 executive orders. We can put $500 million for drug development. And if we don't have people who are willing to hold that space... we're not going to get anywhere." - Ismail Lourido Ali, MAP Co-CEOOn April 18th, just days before 420, Bicycle Day and MAPS’ own 40th anniversary, Donald Trump signed an executive order on psychedelics. But what does it mean? Especially for psychedelic practitioners themselves. Today on the Psychedelic Therapy Podcast I sit down with MAPS Co-Executive Director Ismail Lourido Ali to learn what it actually means for the people doing the work. Together we unpack the executive order from the ground up: what it legally can and can't do, why ibogaine has suddenly kicked down the door while MDMA and psilocybin wait in line, and the strange political alchemy that made this happen. We cover the key distinctions between decriminalization, medicalization, and legalization; MAPS' evolving role as a multicultural bridge-builder at this pivot point; the sovereignty of Gabon and the very real risks of biopiracy in ibogaine's commercialization; and the danger of silver-bullet thinking. The conversation ends with the practitioners themselves, and the irreplaceable human work of preparation, presence, and integration that no executive order can replicate. Ismail Lourido Ali, JD is the Co-Executive Director of MAPS (Multidisciplinary Association for Psychedelic Studies) alongside co-director Betty Aldworth. A philosopher by training and a lawyer by vocation, he previously served as MAPS Director of Policy, worked in criminal justice reform at the ACLU of Northern California, and co-founded the Psychedelic Bar Association. He has been active in psychedelic drug policy reform for over a decade. Timestamps:  (01:00) Ismail's first six months as MAPS Co-CEO (07:00) Decrim, medicalization, legalization (12:00) What Trump's executive order actually does (and doesn't do) (19:00) Why ibogaine? Origins, the opioid crisis, and the perfect storm (30:00) The political alchemy behind the signing (34:00) Where MAPS fits in this pivotal moment (46:00) The Nagoya Protocol, Gabon's sovereignty, and the risk of biopiracy (56:00) Silver bullets vs. real healing Links: Ismail L. Ali, J.D., Co-Executive Director — MAPSIsmail Lourido Ali (@sage_izzy)MAPS Board Names Aldworth and Ali as Co-Executive DirectorsA Practitioner Statement on the Responsible Development of Ibogaine in the United States – Open Letter

Can we practice the art of surrender before the first dose? Today on the show Robin Arnott and Dr. Sandeep Prakash explain how SoundSelf evolved from a VR curiosity into a clinically oriented tool that uses sound and light feedback to induce the unitary states therapists aim for in medicine sessions. We unpack the science of voice-activated biofeedback, ways to weave SoundSelf into preparation and integration protocols, and the larger promise of digital therapeutics for scalable, whole-person care. SoundSelf is a voice-guided, audio-visual platform that primes the nervous system for psychedelic-level surrender and supports post-session integration. Robin Arnott is the former CEO of Andromeda Entertainment, and author of The Technodelic Manifesto. Dr. Sandeep Prakash is a leading Psychedelic Researcher trained at California Institute of Integral Studies. Together they aim to set a new gold standard for tech-enabled mental health. Soundself is launching a new expansion: a tablet pre-configured with SoundSelf. Psychedelic Therapy Podcast listeners who order before May 9 2025 get this $600 upgrade free, plus a two-month evaluation window. Explore it for yourself at: www.soundself.com/ptp Timestamps: (03:46) The Origin and Evolution of SoundSelf(08:15) Exploring the Science and Application of SoundSelf(21:42) Voice Activated Biofeedback and Its Impact(30:47) The Role of SoundSelf in Psychedelic Therapy(35:43) Combining SoundSelf with Psychedelics(38:47) Future of Digital Therapeutics

Imagine you’re in the middle of a psychedelic journey—things are getting intense, and you just need someone to talk to. That’s whereFireside Project comes in. As the world’s first psychedelic peer support line, Fireside is redefining how we care for each other in altered states, offering a space where anyone can find guidance, validation, and a steady voice in uncertain moments. But beyond the helpline, Fireside is also an incredible entry point for those looking to work in the field of psychedelic support. If you’re a practitioner, facilitator, or simply curious about holding space for others, this conversation is for you. In this episode, Fireside Executive Director Joshua White breaks down the essential skills for psychedelic peer support, from understanding the differences between coaching, therapy, and crisis intervention to mastering theart of presence. We explore whyvalidation is often more powerful than de-escalation, the growing importance ofintegration coaching, and the pitfalls ofself-abandonment in the psychedelic industry. Plus, we dig into what it really means toheal the wounded healer—the emotional labor of this work and how to care for yourself while caring for others. Joshua White is the Founder and Executive Director of Fireside Project, a nonprofit dedicated to making psychedelic support accessible and culturally attuned at scale. Through itsPsychedelic Support Line, Fireside provides real-time help for those navigating challenging experiences, while itsFireside-Certified Psychedelic Coaching Program offers deeper, long-term integration support. Before founding Fireside, Joshua was a Deputy City Attorney for San Francisco, where he fought against businesses exploiting vulnerable communities and co-taught a nationally recognized Yale Law School clinic. Now, he’s bringing his passion for advocacy, harm reduction, and healing to the psychedelic space—reshaping how we support one another on these journeys. Timetamps (04:38) Joshua White's Personal Journey(09:00) The Art of Presence(11:48) Distinguishing Peer Support, Coaching, and Psychotherapy(21:07) Fireside Project's Approach to Support(35:46) The Future of Psychedelic Support and AI(41:41) The Need for Long-Term Support in Psychedelic Therapy(47:07) Challenges in the Psychedelic  Industry(52:37) Balancing Personal Well-being and Professional Commitment(59:12) The Importance of Peer Support(01:08:16) Joshua White's Transition Announcement Links Fireside Project: Psychedelic Coaching & Peer Support LineFireside Project (@firesideproject)Curious about becoming Fireside’s new ED?

A month ago, I had the privilege of visiting Beond in Cancun, Mexico to experience an ibogaine treatment for cognitive enhancement. Today, I’m joined by Beond CEO Tom Feegel to discuss how this remarkable medicine can support a better brain. In this episode, we explore Tom’s personal journey with Ibogaine, its potential to revolutionize addiction treatment, and how it supports cognitive enhancement. We discuss key safety concerns, the importance of integrity in healing, and Tom’s reflections on this transformative medicine. Finally, we look ahead to the future of psychedelic access and its impact on mental health worldwide. Tom Feegel is co-founder of Beond Ibogaine, an ibogaine-assisted treatment and research center in Mexico for trauma, PTSD, addiction, and health optimization. He was previously CEO of EO Products, and a founding executive at Brandless. A father of five, Tom lives in Mexico and continues to push boundaries in mental health and addiction recovery. Timestamps 06:25 Tom’s Personal Journey with Ibogaine 10:25 Ibogaine's Impact on Cognitive Enhancement 17:42 Safety Concerns and Proper Use of Ibogaine 27:53 Clinical Environment vs. Shamanic Experience 36:20 Cognitive Enhancement with Ibogaine: Latest Research 40:38 Who Should Consider Ibogaine Therapy? 50:25 The Importance of Integrated Healing 56:41 Access and Inequality in Psychedelic Therapy Links

Today, I’m joined by Juan Pablo Capello, co-founder and former CEO of New Life Health, a telehealth ketamine therapy service launched in 2021. Juan Pablo has raised concerns about low standards of care in telehealth ketamine, making this a timely conversation about the opportunities and challenges in this growing industry. In our discussion, Juan Pablo shares how his early experiences with Wachuma inspired his interest in psychedelics for mental health. We address key topics, including the potential for ketamine addiction, the impact of Matthew Perry’s death on the psychedelic community, and the surprising role of insurance companies in shaping telehealth standards. We also explore the Religious Freedom Restoration Act, Juan Pablo’s work with the Eagle Condor Church, and how integration is best approached as a community effort. Juan Pablo is a seasoned entrepreneur who co-founded a leading Latin American crowdfunding platform and a creative campus in Miami’s Wynwood Arts District. As the former CEO of New Life Health, now part of Beckley Waves, he continues to engage in work that bridges innovation, care, and community in the psychedelic space. Timestamps (06:00) Juan Pablo’s background in Chile and his experience with Wachuma (11:30) Why ketamine is used in mental health treatment (21:00) Is ketamine addictive? (25:00) Matthew Perry’s death as a wake-up call for the ketamine community (36:00) The surprising regulatory influence of insurance companies (41:00) The Religious Freedom Restoration Act and the Eagle Condor Church (53:00) The lack of integration in traditional psychedelic therapy contexts (57:00) Integration as a community-driven process Links Juan Pablo Cappello - PAG Law PLLC Matthew Perry's Death Shows Ketamine Industry Needs a Wakeup Call Nue Life | At Home Ketamine Therapy

Today, we’re exploring a critical issue facing the field of psychedelic medicine: the recent FDA rejection of MAPS’ clinical trials to reschedule MDMA for therapeutic use. This setback affects many of us committed to healing and transforming society through psychedelics.  To help us understand the impact and the path forward, I’m joined by Natalie Lila Ginsberg, a leading voice in the psychedelic field and MAPS’ Global Impact Officer. In this episode, Natalie and I discuss the importance of psychedelic therapy and her personal passion for this work. We cover the history of MDMA’s criminalization, the complexities of the FDA’s decision, and the split between MAPS and its public benefit corporation, Lycos. Natalie sheds light on why the FDA remains cautious and how psychedelic therapy may or may not fit into the Western medical model. Finally, she offers guidance for aspiring psychedelic therapists on the most valuable trainings and credentials to pursue. Natalie has led MAPS’ Policy and Advocacy Department, co-developed their Health Equity Program, and now champions the ethical integration of psychedelics into mainstream culture. Before MAPS, she was instrumental in legalizing medical cannabis in New York, and she co-founded the Jewish Psychedelic Summit. TIMESTAMPS (10:20) — What is psychedelic therapy and why is it important (17:00) — Natalie’s WHY (24:00) — Why MDMA is illegal (31:30) — Why the advisory board recommended the FDA not to deschedule  (34:00) — Why there was a split between the nonprofit MAPS and public benefit corp Lycos (41:45) — Why is the FDA so cautious (48:00) — Can psychedelic therapy ever truly fit into the Western medical model? (56:00) — Natalie’s recommendations for trainings and credentials that are worth investing in for psychedelic therapists LINKS Debunking FDA Advisory Meeting with Lauren Taus Multidisciplinary Association for Psychedelic Studies – MAPS Natalie Lyla Ginsberg, M.S.W. Global Impact Officer Natalie Lyla Ginsberg (@natalielyla)

Today we’re doing something a little different. I’m re-releasing an episode from my personal podcast, Life is a Festival, because it remains one of my favorite interviews ever. This conversation, originally recorded a few years ago, is with Tricia Eastman and Joseph Barsuglia, two pioneers in the world of psychedelic medicine. We dive deep into Iboga, the Bwiti people of Gabon, and the powerful pharmacology of this unique plant medicine. I wanted to share it with you as it remains highly relevant and educational. In this episode, we explore Iboga and its cultural and spiritual significance. We discuss the Bwiti people, their rituals and music, and how these elements interweave with Iboga's healing properties. Tricia and Joseph share their journeys as healers, their work with Iboga, and its connection to other psychedelics like 5-MeO-DMT. We also touch on the subject of microdosing Iboga and its suitability for this practice. Joseph and Tricia both worked at Crossroads ibogaine treatment center in Mexico. Joseph has co-led psychedelic retreats around the world since 2015 and serves as an advisor to numerous psychedelic medicine companies. Tricia Eastman is a renowned speaker and healer, with her book Seeding Consciousness: Plant Medicine, Ancestral Wisdom, and Psychedelic Initiation launching November 12, 2024. Together, they bring a wealth of wisdom to today’s discussion. Timestamps: (08:00) - Who are the Bwiti (17:00) - The Pharmacology of Iboga (29:00) - The meaning of Bwiti music and rituals (38:30) - Tricia and Joseph’s journeys to iboga  (46:30) - 5MeoDmt  (52:00) - Overcoming spiritual ego and supporting conservation (1:04:30) - Microdosing iboga  Links: Seeding Consciousness - Simon & Schuster Dr. Joseph Peter Barsuglia psychedelicjourneys - Tricia Eastman

After the shocking decision of an advisory committee recommendation that the FDA reject MDMA as a treatment for post-traumatic stress disorder, I wanted to speak to someone who understands the difference between clinical trials and private practice. Dr. Jennifer Tippett is a licensed clinical psychologist and Director of Psychotherapeutic Development at atai Life Sciences, where she creates therapeutic protocols and provides facilitator training for psychedelic clinical trials. On the show, we start with Jennifer’s experience in forensic psychology. Then we discuss the difference between industry trials, academic trials, and private practice. We talk about making novel psychedelics, and if it is possible, or desired, to make a psychedelic that doesn’t have the trip. We also discussed equity and access, including both cultural and financial barriers to psychedelic healing. Jennifer has spent a lot of time considering how one might create a sustainable business model for psychedelic therapy, especially looking at what has been going on in Oregon. As an employee of atai Life Sciences, which is a publicly traded company, Jennifer responds to some criticisms of for-profit psychedelic companies. And finally, we end with her response to the recent FDA advisory finding against using MDMA for post-traumatic stress disorder. Jennifer previously directed the Substance Use Disorder Specialty Program at the University of Denver, focusing on addiction and the neurobiology of trauma. Her early career involved working with incarcerated individuals and those with severe mental illness, inspiring her to explore innovative mental health care, including psychedelic medicine. Dr. Tippett studied psychedelics through shamanistic traditions and obtained certifications from Fluence, Polaris, MAPS, and the Integrated Psychiatry Institute. She is also a Level 1 Internal Family Systems provider, dedicated to integrating psychedelics with evidence-based therapies. In her private practice she supports clients with psychedelic integration.  The views and opinions expressed by Jennifer in this episode are her own and do not necessarily represent those of atai Life Sciences.  Links Integration | Jennifer Tippett psychologist Jennifer Tippett, Ph.D. atai Life Sciences Timestamps (07:00) - Could psychedelic therapy help treat psychopathy?  (15:30) - The difference between industry trials, academic trials, and private practice (20:30) - Should we make new psychedelics? (25:00) - Equity and access, culturally and financially (30:30) - Creating sustainable business models for psychedelics therapists (35:30) - Could we have healing without the trip? (39:30) - Responding to criticism of for profit psychedelic companies (42:30) - Responding to FDA advisory board’s decision on MDMA

A year and a half ago, I went on an antidepressant medication, Wellbutrin, which is a dopamine and norepinephrine reuptake inhibitor. After 20 years of plant medicine, meditation, therapy, and other healing modalities, which I still use, I was still experiencing persistent challenges. With the support of my advisors and my doctor, I decided to an antidepressant while maintaining my alternative healing practices. Today on the show I discuss the intersection of psychopharmacology and psychedelics with a psychiatric pharmacist, Ben Malcolm. On the show, we talk about how Ben became a psychedelic pharmacist and how he created his website, Spirit Pharmacist. We discuss the origins of mental health treatment, the use of psychedelics and psychotropics together, and important contraindications for LSD, psilocybin, MDMA, ketamine, and ayahuasca. We cover the process of tapering off antidepressants, the reasons behind it, how it works, and the period needed for tapering. Ben also speaks directly to psychedelic practitioners. This is offered for informational purposes only, and I would direct you to Ben Malcolm's website for more specific answers. Ben Malcolm is a psychopharmacologist and professor of pharmacy with experience in plant medicine and psychedelics. He helps people get off psychiatric meds for journeys and is available to help you or your clients if you are in the healing arts. Ben Malcolm is a board-certified psychiatric pharmacist with a passion for psychedelic drugs, antipsychotics, antidepressants, and alternative medicines. He offers psychopharmacology consulting, educational courses, and a membership program at his website Spirit Pharmacist. Links Psychedelic Psychopharmacology Consulting and Education Spirit Pharmacist (@spiritpharmacist) Timestamps (09:30) - How Ben became a psychedelic pharmacist (14:30) - The origins of mental health treatment (21:30) - Using psychedelics with psychotropics (29:00) - Contraindications for LSD, psilocybin, MDMA, ketamine, and ayahuasca (45:00) - Tapering off antidepressants (59:00) - Ben speaks to psychedelic practitioners

Welcome back to the Psychedelic Therapy Podcast. I'm your host, Eamon Armstrong. Today on the show, we're welcoming back Tony Moss. Tony is an artist, producer, and member of the Bird Tribe Music Collective. He is also an ayahuasca facilitator with 30 years of experience and has just released a new album, Joy. In today's conversation, we discuss the magic and science of medicine music. We talk about the state of medicine work in 2024, why psychedelics change the way we hear music, and the difference between an Icaro, a medicine song, and other genres. We also explore the hymns of Santa Daime, Tony's gospel-inspired music, and his new album, Joy, which turns unexpected genres into medicine music. Tony is a recording artist, producer, and creative director. Born into a musical family of R&B gospel singers, he was raised in California's psychedelic and spiritual cultures. Inspired by over 25 years of working with plant medicines, Tony combines science, shamanism, and multiple music genres to create music dubbed "Soulful Ceremonial." Timestamps (05:00) - The state of medicine work in 2024 (10:30) - Why do psychedelics change how we hear music (18:30) - The difference between an icaro and a medicine song (29:00) - Some songs are medicine but not medicine music (35:00) - The Hymns of Santo Daime and Tony’s own Gospel inspired song Grateful   (42:30) - Does speaking without song work? (50:00) - Tony’s album Joy and making medicine music out of unexpected genres Links Tony Moss: Medicine Music Tony Moss (@mosstony) JOY | Tony Moss, Bird Tribe Previous Podcasts Tony Moss (I.AM.LIFE): So You Want to Be a Shaman? From Activist to Ayahuasca Advocate | Tony Moss (Bird Tribe) Ayahuasca for Healing Ancestral Racial Trauma | Tony Moss

Welcome back to the Psychedelic Therapy Podcast. After a hiatus of a year and a half, we're excited to announce our return, thanks to our new sponsors, Hurricane Lotus (formerly Maya, the original sponsor of this show) and Holos Global, we are now back and releasing regular episodes. On today's show, I’m speaking with Alexander Beiner, author of "The Bigger Picture: How Psychedelics Can Help Us Make Sense of the World." We discuss the roots of the mental health crisis, the role of psychedelics in healing, and what healing actually means according to Beiner. We also explore understanding existential risks and how this relates to psychedelic healing, as well as the ethical dilemmas in psychedelic healing. We conclude our conversation with Alexander's account of his extended state DMT experience at Imperial College London and his belief in the power of the teaching presence. Alexander Beiner is a writer, cultural commentator, and podcaster. He's one of the founders of Rebel Wisdom, a media and events organization with a quarter of a million subscribers and a focus on making sense of culture and complexity. He's also an executive director of Breaking Convention, Europe's longest-running conference on psychedelic science and culture. He is a leading critical and countercultural voice in the "psychedelic renaissance" and has produced a number of films, articles, and events at the leading edge of the conversation about the potential of psychedelics. Timestamps: (07:00) - The Roots of the Mental Health Crisis (13:00) - The Role of Psychedelics in Healing (23:00) - Understanding Existential Risks and Psychedelic Healing (33:30) - Ethical Dilemmas in Psychedelic Healing (42:30) - Alexander’s Extended State DMT Experience and the Teaching Presence Links: Alexander Beiner: Sensemaking The Bigger Picture The Bigger Picture | Alexander Beiner | Substack Alexander Beiner (@alexander_beiner) Breaking Convention

Today on the show we are discussing the state of psychedelic legislation in the wake of Colorado’s Proposition 22 passing in November. Sharing the most relevant implications for psychedelic therapists and healers we have the best person for the job, MAPS Director of Policy and Advocacy Ismail Lourido Ali. On the show we discuss legalization vs decriminalization. We look at the different tracks for psychedelic legalization from medicalization to religious exception to regulated adult use. We discuss Oregon’s Bills 109 and 110 exploring “scope of practice,” residency laws, and training reciprocity. We look at Colorado’s Proposition 22 and the two big differences between that and what was passed in Oregon two years ago. We discuss equity initiatives. Ismail shares what legalization efforts look like on the federal level and to close our conversation, he speaks directly to psychedelic healers. As MAPS’ Director of Policy and Advocacy, Ismail advocates to eliminate barriers to psychedelic therapy and research, develops and implements legal and policy strategy, and supports MAPS’ governance, non-profit, and ethics work. Ismail earned his J.D. at the University of California, Berkeley School of Law in 2016, after receiving his bachelor’s in philosophy from California State University, Fresno. Ismail has previously worked for the ACLU of Northern California’s Criminal Justice & Drug Policy Project, and Berkeley Law’s International Human Rights Law Clinic. Ismail is licensed to practice law in the state of California, and is a founding board member of the Psychedelic Bar Association. Ismail is passionate about setting sustainable groundwork for a just, equitable, and generative post-prohibition world. Timestamps :06 - Izzy’s role as Director of Policy and Advocacy for MAPS :10 - Legalization vs decriminalization :16 - Religious exception vs medicalization :22 - Oregon’ regulated adult use system (Bill 109) :28 “Scope of practice” and psilocybin facilitation licenses in Oregon. :34 - Information for practitioners hoping to offer services in Oregon or Colorado including residency laws and training reciprocity :40 - Two big differences in the recently passed Colorado’s Prop 22 :47 - Equity initiatives in Oregon and Colorado :54 - What can we anticipate around federal legislation in psychedelics Links Izzy’s Instagram Izzy Twitter Multidisciplinary Association for Psychedelic Studies - MAPS MAPS Twitter MAPS Instagram Psychedelic Bar Association Guide to RFRA and Best Practices for Psychedelic Plant Medicine Churches Oregon Health Authority MAPS analysis regarding Oregon’s Measures 109 and 110 passed in Nov 2020 MAPS analysis regarding Colorado Proposition 122 MAPS analysis regarding our work on SB519 in CA to decriminalize the personal use of all psychedelics

Could enhancing creativity be the key to healing mental illness? Laura Dawn of Grow Medicine, makes a compelling case for the value of psychedelics for enhancing flow. Our conversation begins with an exploration of eldership and indigenous concepts of reciprocity based on Laura Dawn’s recent trip to Columbia. Laura Dawn gives us practical tools for enhancing creativity and makes the case for psychedelic healing through optimizing flow states. We conclude with how to prevent burnout amongst healers, facilitators, and other leaders in the psychedelic space. Laura Dawn hosts The Psychedelic Leadership Podcast and is the founder & director of Grow Medicine. She has a Masters in Science specializing in Creativity Studies & Change Leadership and is at the forefront of exploring the intersection between psychedelics and creative cognition for leadership development. Timestamps :05 - Laura’s trip to Colombia to learn from the Kogi and Mamos indigenous elders :19 - How to best innervate psychedelics into the mainstream :24 - Focusing on the intersection between psychedelics and creative cognition :34 - Healing mental illness through creativity tools for accessing creative cognition :49 - How to prevent burnout amongst healers, facilitators, and people in the psychedelic space Links Grow Medicine Website Laura Dawn Website Instagram

Can sound help us disconnect from unhealthy habitual patterns? Today’s guest Alexandre Tannous, creator of the Sound Meditation protocol, shows how we can use harmonic frequencies to release trauma, enhance self-awareness and live happier, healthier lives. Our conversation begins with Alexandre’s explanation of harmonic frequencies and the problem with the quantization of the 12-tone scale. We discuss the value of sound in the context of psychedelic experiences, as well as sound meditation protocols (set and setting). We conclude with issues that need to be addressed when working with these powerful tools. Alexandre Tannous is an ethnomusicologist, sound therapist, and sound researcher. He is also the Principal Founder of ResonantMind Collective. For the past 22 years Alexandre has been researching the therapeutic and esoteric properties of sound from three different perspectives – Western scientific, Eastern philosophical, and shamanic societal beliefs – to gain a deeper understanding of how sound has been used to affect human consciousness. This search has led him to where art, science, philosophy, and spirituality intersect. He continues to do research on sound, currently works as a sound therapist, teaches the method he has created, and lectures about sound throughout the world. Timestamps :08 - An overview of sound and the 12 tone scale :20 - The problem with calling supplements “plant medicine” Ability to experience the transformational quality of sound in the context of a psychedelic experience :28 - Default mode network :37 - Alexandre’s specific protocol for Sound Meditation :44 - The impact of the Sound Meditation Protocol :54 - The pitfalls of powerful tools and the parasitic force Links Alexandre Tannous Website Resonant Mind Collective

In the United States, 20 million women and 10 million men suffer from a clinically significant eating disorder at some time in their life. And as psychedelics are becoming more mainstream, there is an increased interest in using new tools to overcome these disorders. Today, with guest Adele Lafrance, we discuss the promising impact that ayahuasca, MDMA, ketamine, and psilocybin can have on a person who is struggling to heal from disordered eating. We begin our conversation by discussing the challenges of healing eating disorders and how psychedelics can help. Adele then shares her work with Emotion-Focused Family Therapy (EFFT), and resources that are specific to clinicians. She speaks on ayahuasca as a healing modality with the unique concerns of ayahuasca preparation diets and the importance of integration. We close with discussing MDMA, psilocybin, and ketamine as treatment options, and the importance of love in healthcare. Dr. Adele Lafrance is a clinical psychologist, research scientist, author, and developer of Emotion-Focused Family Therapy (EFFT). She is a leader in the research and practice of psychedelic medicine, with a focus on ayahuasca, MDMA, psilocybin, and ketamine. Currently, Adele is the clinical investigator and strategy lead for a MAPS-sponsored study of MDMA-assisted psychotherapy. Links: Adele Lafrance Adele's Twitter  Dr. Rachel Yehuda  Gabor Mate  The Jungle Prescription  Emotion-Focused Family Therapy Book  Emotion-Focused Therapy Website EFFT Institute  Timestamps :05 - Challenges of healing from an eating disorder and ayahuasca for treatment :15 - Adele’s introduction to working with eating disorders and Emotion-focused family therapy (EFFT) :21 Resources for EFFT and specific techniques for clinicians :31 - Findings with ayahuasca as a healing modality for eating disorders, and psychedelic integration :36 - Training to bring practitioners up to speed on eating disorders :43 - MDMA and its treatment with PTSD :48 - Ketamine and eating disorders :50 - The importance of talking about love in psychedelic research